Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04554069
Collaborator
(none)
280
8

Study Details

Study Description

Brief Summary

Assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately.

    Thiazide-type diuretics, angiotensin-converting enzyme (ACE) inhibitors and some of angiotensin-II receptor blockers (ARB) were reported to reduce renal excretion of urate and increased serum uric acid levels, Beta-blockers also elevate serum uric acid levels.

    Hyperuricemia is a risk factor for cardiovascular diseases. Hyperuricemia was found to correlate with hypertension excluding the influence of other factors such as age and renal function. Furthermore, many studies found that hyperuricemia was independently associated with cardiovascular events in patients treated with antihypertensive drugs.

    It is important to control serum uric acid levels in hypertensive patients treated with antihypertensive drugs in order to reduce the risk of gout and cardiovascular events. There is a gap in knowledge in studies showing the effect of antihypertensive drugs on serum uric acid in newly diagnosed hypertensive patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    280 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients
    Anticipated Study Start Date :
    Jun 1, 2021
    Anticipated Primary Completion Date :
    Jan 1, 2022
    Anticipated Study Completion Date :
    Feb 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. The effect of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension. [6 months from baseline]

      we will measure the change of the level of serum uric acid after 6 months from the treatment of antihypertensive durgs

    Secondary Outcome Measures

    1. obesity [6 months from baseline]

      it will be measured by BMI (kg/m2)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • All newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study
    Exclusion Criteria:
    1. Patients below 30 years old.

    2. Patients with kidney disease.

    3. Patients who are taking medications known to increase SUA as (Thiazide and Loop diuretics, Salicylates, Cyclosporin use) or decrease the level of uric acid in the urine as (Allopurinol, Febuoxstate).

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Principal Investigator: Dalia Mahran, Professor, faculty of medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dalia Mahran, Professor of Public Health and Community Medicine, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04554069
    Other Study ID Numbers:
    • Uric acid in Hypertension
    First Posted:
    Sep 18, 2020
    Last Update Posted:
    Jan 22, 2021
    Last Verified:
    Jan 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 22, 2021